HONG KONG – With the advantage of an English-speaking population, precision manufacturing capabilities and courts dedicated to solving intellectual property matters, Malaysia is quickly emerging as a launch pad for biopharmaceutical companies looking to enter the Asian market and regional companies aiming to expand.
HONG KONG – The health care industry in China could go through a period of flux over the next year as it responds to widespread changes to the country's economy.
TOKYO – Japan, with the world's third-highest rate of stomach cancer behind Mongolia and the Republic of Korea, will soon have another combination drug mix to help treat the disease.
SHANGHAI – Sciclone Pharmaceuticals Inc. has had a pretty good year. The company continues to grow in the double digits and has hit revenue expectations for several quarters, helping to push stock prices to a rosy $8 to $9 range from a depressed low of $4 last year. It has shown that it can ride out the end of a significant commercial contract with Sanofi SA without much damage, as well as live with the reality of a seemingly never-ending SEC investigation.
Protein Sciences Corp., of Meriden, Conn.; UNM Pharma Inc., of Akita, Japan; and IHI Corp., of Tokyo, said they entered an agreement to assess the feasibility of sourcing the active ingredients of Flublok influenza vaccine from Japan. The drug substances would be manufactured at the Gifu (Japan) plant of Unigen, a subsidiary of UMN Pharma in which IHI holds 50 percent of the common shares.
SHANGHAI – China has announced that it will be initiating phase I trials for Ad5-Ebov, a recombinant adenoviral Ebola vaccine co-developed by the Bioengineering Institute of the Chinese Academy of Military Medical Sciences (AMMS) and vaccine start-up Tianjin Cansino Biotechnology Inc.
HONG KONG – Research into the different mechanisms contributing to the development of antibiotic resistance may lead not only to the discovery of new methods for preventing the acquisition of microbial resistance, but also potentially may result in the development of new antibiotics, according to Japanese scientists
NEW DELHI – India's Supreme Court has dismissed German multinational Bayer AG's appeal against attempts to make and sell cheaper generic versions of its cancer drug, Nexavar (sorafenib tosylate), used to treat liver and rectal cancers.
SHANGHAI – Eddingpharm Co. Ltd. will develop and commercialize Cardiome Pharma Corp.'s atrial fibrillation drug, Brinavess (vernakalant), paying $1 million up front for the Greater China rights with potential for the Vancouver, British Columbia-based Cardiome to receive $3 million more in regulatory milestone payments.
RSS